Geographic Atrophy

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

Curative Biotechnology Inc. has completed and filed a patent cooperation treaty (PCT) application with the U.S. Receiving Office.

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

Data demonstrate a reduction in the loss of retinal pigmented epithelial and photoreceptor cells.

The company made these announcements at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.

David S. Boyer, MD, senior partner at Retina Vitreous Associates Medical Group, shares key takeaways from "Advances in geographic atrophy," which he co-presented.

Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).

Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.

Apellis Pharmaceuticals Inc. delivered an oral presentation at the ARVO Annual Meeting in New Orleans announcing their post hoc analyses from the Phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy (GA).

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

Researchers conducted clinical imaging and histopathologic studies to gain a better understanding of geographic atrophy (GA) in 3 siblings.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

Imaging biomarkers are useful to determine the degree of EZ attenuation in the fovea.